Having made a habit of defending St. Jude Medical (NYSE: STJ )
as it navigated its way through a lull in growth, doubts about its
clinical pipeline, and the controversy over its Riata leads, it feels a
little strange to complain that the shares now appear to be overvalued.
And yet, even though I'm bullish on the prospects for products like
Portico, MediGuide, CardioMEMS, and Nanostim, it's hard to come up with a
realistic set of growth expectations that suggest these shares are too
cheap today.
Read more here:
St. Jude Medical Inc.'s Valuation Already Looking Pretty Racy
No comments:
Post a Comment